COMMUNIQUÉS West-GlobeNewswire

Revium Rx Advances Toward Phase 1 Clinical Development of Nano-Mupirocin to Combat Antibiotic-Resistant Infections
21/10/2025
TEL AVIV, Israel, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Revium Rx (formerly Revium Recovery Inc. (OTC: RVRC), a biopharmaceutical company developing advanced lipid-based therapeutics for infectious and oncologic diseases, [...]
Dermsquared Appoints April Armstrong, MD, MPH, as Editor-in-Chief of the Dermatology Online Journal
21/10/2025
Plano, Texas , Oct. 21, 2025 (GLOBE NEWSWIRE) -- Dermsquared , the leading community-based platform for dermatology professionals, today announced the appointment of April Armstrong, MD, MPH, as Editor-in-Chief of the [...]
Step Pharma to spotlight work in CTPS2-null solid tumours at 2025 EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics
21/10/2025
Saint-Genis-Pouilly, France, 21 October 2025 – Step Pharma (“the Company”), the global leader in CTPS1 inhibition for targeted cancer treatment, today announces that its Chief Scientific Officer, Philip Beer, will be [...]
KFSHRC réalise la première résection robotisée au monde d’une tumeur intracrânienne... Une nouvelle ère en neurochirurgie
21/10/2025
RIYAD, Arabie saoudite, 21 oct. 2025 (GLOBE NEWSWIRE) -- Dans une avancée historique pour la robotique médicale, le King Faisal Specialist Hospital and Research Centre (KFSHRC) de Riyad a réalisé avec succès la première [...]
Alignment Health Plan Joins Forces with Suvida Healthcare to Expand Bilingual Care, Access for Arizona Seniors
21/10/2025
New agreement brings culturally attuned, neighborhood-based care to 1+ million Medicare-eligible adults in Maricopa and Pima counties PHOENIX, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Alignment Health Plan , an award-winning [...]
RadNet to Host Investor Day on November 11, 2025
21/10/2025
LOS ANGELES, Oct. 21, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of outpatient imaging centers and [...]
RYBREVANT®▼ par voie sous-cutanée (amivantamab) offre un taux de réponse global prometteur de 45 pour cent associé à une durée de réponse médiane de 7,2 mois dans le cancer de la tête et du cou récurrent ou métastatique
21/10/2025
Les réponses étaient rapides et durables, et une réduction tumorale a été observée chez 82 pour cent des patients 1 Les nouveaux résultats issus de cette étude expérimentale s’appuient sur la solidité des données [...]
Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2025 American College of Rheumatology (ACR) Convergence
21/10/2025
CHATHAM, N.J., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated, commercial biotechnology company, announced today that a poster on [...]
Standard BioTools to Announce Third Quarter Financial Results on November 4, 2025
21/10/2025
SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will publish third quarter 2025 financial results on Tuesday, November 4, 2025, after U.S. [...]
Climb Bio Names Adam Villa as SVP, Technical Operations and Ashley Jones as SVP, People & Workforce Strategy
21/10/2025
WELLESLEY HILLS, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced that it has [...]
SynOx Therapeutics Strengthens Board of Directors with Leading Experts in Commercialisation and Corporate Development Amid Continued Corporate Progress
21/10/2025
Charles “Chip” Romp and Tom Heyman join SynOx’s Board, bringing deep launch, lifecycle, and corporate development expertise as the company advances its next-generation therapy emactuzumab toward key regulatory and [...]
Sionna Therapeutics Announces Initiation of PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, When Added to Standard of Care in Participants with Cystic Fibrosis
21/10/2025
SION-719 is the first NBD1 stabilizer being evaluated in people living with cystic fibrosis Topline data expected in mid-2026 WALTHAM, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a [...]
Hengrui Pharma and Kailera Therapeutics Announce Phase 3 HRS9531 Obesity Data Presentation at ObesityWeek® 2025
21/10/2025
Results from Hengrui’s completed Phase 3 clinical trial of HRS9531, a novel dual GLP-1/GIP receptor agonist with potentially best-in-category weight loss, to be presented in an oral session SHANGHAI and WALTHAM, Mass., [...]
Flare Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate FX-909 in Combination with KEYTRUDA® (pembrolizumab) in New Cohort of Ongoing Phase 1 Trial in Metastatic Urothelial Cancer
21/10/2025
CAMBRIDGE, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for oncology and other [...]
InflaRx Announces Participation in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference
21/10/2025
JENA, Germany, Oct. 21, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced its participation [...]
Clearmind Medicine Enrolls Last Patient for the First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder
21/10/2025
Vancouver, Canada, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel [...]
Plus Therapeutics Updates on CNSide® Diagnostic Platform Launch
21/10/2025
Expands commercial readiness and diagnostic, manufacturing footprint Appoints new leadership in commercial strategy and technical operations HOUSTON, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: [...]
BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+™ for Breast Cancer
21/10/2025
Collaboration with MSK’s Therapeutics Accelerator Program includes manufacturing, IND and clinical development support of the Bria-OTS+™ platform, which includes Bria-BRES+™ for breast cancer PHILADELPHIA and VANCOUVER [...]
BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study
21/10/2025
79 clinical sites across 23 US states are currently enrolling patients in BriaCell’s pivotal Phase 3 study in metastatic breast cancer (MBC) Dartmouth Cancer Center, Cedars-Sinai Medical Center, and Winship Cancer [...]

Pages